Mayte Sánchez van Kammen, MD; Diana Aguiar de Sousa, MD, PhD; Sven Poli, MD, MSc; et al.
free access
JAMA Neurol. 2021;78(11):1314-1323. doi:10.1001/jamaneurol.2021.3619
This cohort study describes the clinical characteristics and outcome of patients with cerebral venous sinus thrombosis after SARS-CoV-2 vaccination with and without thrombosis with thrombocytopenia syndrome.
Jacobo Mintzer, MD, MBA; Krista L. Lanctôt, PhD; Roberta W. Scherer, PhD; et al.
free access
JAMA Neurol. 2021;78(11):1324-1332. doi:10.1001/jamaneurol.2021.3356
This randomized clinical trial measures whether methylphenidate compared with placebo decreases the severity of apathy in individuals with Alzheimer disease.
Margherita Nosadini, MD, PhD; Michael Eyre, MD; Erika Molteni, PhD; et al.
open access
has audio
JAMA Neurol. 2021;78(11):1333-1344. doi:10.1001/jamaneurol.2021.3188
This meta-analysis evaluates the use and safety of immunotherapies among patients with N-methyl-d-aspartate receptor antibody encephalitis.
-
Podcast:
Use and Safety of Immunotherapeutic Management of N-Methyl-D-Aspartate Receptor Antibody Encephalitis
Keith Vossel, MD, MSc; Kamalini G. Ranasinghe, MBBS, PhD; Alexander J. Beagle, MD; et al.
free access
JAMA Neurol. 2021;78(11):1345-1354. doi:10.1001/jamaneurol.2021.3310
This randomized clinical trial uses extended neurophysiological examinations to assess the ability of levetiracetam treatment to improve cognitive function among adults with Alzheimer disease with and without epileptiform activity.
Wei Gu, MD, PhD; Andreas M. Rauschecker, MD, PhD; Elaine Hsu, BS; et al.
free access
JAMA Neurol. 2021;78(11):1355-1366. doi:10.1001/jamaneurol.2021.3088
This case-control study evaluates the use, sensitivity, and specificity of the cerebrospinal fluid metagenomic next-generation sequencing assay in identifying aneuploidy and other large copy number variations.
Colin B. Josephson, MD, MSc; Samuel Wiebe, MD, MSc; Guillermo Delgado-Garcia, MD, MSc; et al.
free access
JAMA Neurol. 2021;78(11):1367-1374. doi:10.1001/jamaneurol.2021.3424
This cohort study compares the risk associated with enzyme-inducing antiseizure medications and non鈥揺nzyme-inducing antiseizure medications in individuals with cardiovascular disease.
Shorena Janelidze, PhD; Charlotte E. Teunissen, PhD; Henrik Zetterberg, MD, PhD; et al.
open access
JAMA Neurol. 2021;78(11):1375-1382. doi:10.1001/jamaneurol.2021.3180
This cross-sectional study compares the performance of plasma amyloid-尾 42/40 (A尾42/40) measured using 8 different A尾 assays and methods in detecting abnormal brain A尾 status in patients with early Alzheimer disease.